Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Inclusion Criteria: 1. Patients who have provided written informed consent 2. Patients who have urothelial cell carcinoma of the bladder with clinically apparent stage Ta, grade G1-G2 and satisfy both of the following criteria: * The maximum number of tumors is 5. * Each tumor diameter: ≤ 3.5 cm. 3. Age: ≥20 years old at enrollment. 4. The functions of the major organs are adequate, and the following test value criteria are satisfied: * Neutrophil count ≥1,500/μL * Platelet count ≥10×10\^4/μL * Hemoglobin ≥10 g/dL Exclusion Criteria: 1. Patients with a single, primary bladder cancer of \<0.5 cm. 2. Patients with CIS lesions in the bladder or a history thereof. 3. Patients with a history of other than stage Ta, histological grade G1 or G2 disease. 4. Patients experiencing recurrence within 4 months following TURBT for prior NMIBC (duration between the last TURBT and cystoscopic confirmation of the present recurrence is within 4 months). 5. Patients without at least a three-month cystoscopically confirmed recurrence-free interval between the last TURBT and the time of study screening 6. Patients having a bladder tumor with a histological diagnosis other than urothelial carcinoma of the bladder or a history thereof. 7. Patients who had been administered EO9 in the past. 8. Patients who had been administered any other investigational drug within the past 30 days. 9. Patients having a medical condition that would make it unsafe for them to undergo TURBT under general or spinal anesthesia.